212 related articles for article (PubMed ID: 36715573)
21. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancer.
Zhu Y; Ren W; Li S; Wu J; Hu X; Wang H; Chi K; Zhuo M; Lin D
Virchows Arch; 2024 Feb; ():. PubMed ID: 38347268
[TBL] [Abstract][Full Text] [Related]
23. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
[TBL] [Abstract][Full Text] [Related]
24. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
25. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
27. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
[TBL] [Abstract][Full Text] [Related]
28. Small cell lung cancer - news in the tumour´s biology.
Pavlíčková K; Matěj R
Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
[TBL] [Abstract][Full Text] [Related]
29. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
30. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
31. Dynamic transition of molecular subtypes in relapsed small cell lung cancer treated with multimodal therapy: A case report.
Yasuda K; Haruki T; Miyamoto T; Oshima Y; Matsui S; Kubouchi Y; Nakamura H
Thorac Cancer; 2023 Jul; 14(20):2001-2004. PubMed ID: 37253435
[TBL] [Abstract][Full Text] [Related]
32. POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.
Szczepanski AP; Tsuboyama N; Watanabe J; Hashizume R; Zhao Z; Wang L
Sci Adv; 2022 Oct; 8(40):eabq2403. PubMed ID: 36197978
[TBL] [Abstract][Full Text] [Related]
33. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
34. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
35. Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma.
Zhu Y; Li S; Wang H; Chi K; Ren W; Huang X; Zhuo M; Lin D
Hum Pathol; 2023 Nov; 141():118-129. PubMed ID: 37586462
[TBL] [Abstract][Full Text] [Related]
36. [Heterogeneity of small cell lung cancer: biological and clinicopathological implications].
Megyesfalvi Z; Bárány N; Valkó Z; Bugyik E; Paku S; Berta J; Lantos A; Fillinger J; Moldvay J; Bogos K; Rezeli M; Gálffy G; Lang C; Lohinai Z; Hécz R; Lovas T; Rényi-Vámos F; László V; Döme B
Magy Onkol; 2020 Sep; 64(3):243-255. PubMed ID: 34608895
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
[TBL] [Abstract][Full Text] [Related]
38. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract][Full Text] [Related]
39. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
40. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]